MedTrace Logo

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

NCT00886782 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-04-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.

Conditions

Interventions

DRUG

Cdc7-inhibitor

Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-08-04
Completion
2010-08-04
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00886782 on ClinicalTrials.gov